Name: UMIN ID:
Unique ID issued by UMIN | C000000011 |
---|---|
Receipt number | R000000020 |
Scientific Title | Study of cyclophosphamide, epirubicin and fluoraouracil followed by docetaxel (CEF-DOC) as preoperative chemotherapy in primary operable breast cancer |
Date of disclosure of the study information | 2005/06/22 |
Last modified on | 2019/11/21 15:58:03 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2005/06/14 10:43:48 | ||
2 | Update | 2005/06/22 09:35:56 | UMIN ID1 |
|
3 | Update | 2005/06/22 09:38:31 | Institute Category of Funding Organization Institute Date of disclosure of the study information |
|
4 | Update | 2005/06/24 10:35:07 | Address TEL Address |
|
5 | Update | 2005/06/24 10:36:06 | Key inclusion criteria |
|
6 | Update | 2005/07/11 14:59:33 | Organization Last name of lead principal investigator Organization Division name Last name of lead principal investigator Division name |
|
7 | Update | 2005/08/17 09:26:29 | Public title Acronym Acronym |
|
8 | Update | 2005/08/17 09:33:48 | Interventions/Control_1 Interventions/Control_1 |
|
9 | Update | 2005/10/12 11:48:46 | Division name Organization Organization Division name Division name Address Address TEL |
|
10 | Update | 2007/02/02 16:03:41 | Other related information Other related information |
|
11 | Update | 2008/06/16 08:28:44 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded Publication of results Results Results |
|
12 | Update | 2008/06/19 16:06:58 | UMIN ID2 |
|
13 | Update | 2008/06/23 10:48:22 | Address Address Address TEL Address Address TEL Organization1 Address1 Tel1 Email1 |
|
14 | Update | 2008/06/25 15:59:06 | Organization Organization Division name Division name Address Address TEL Organization |
|
15 | Update | 2013/06/17 16:05:43 | Acronym Acronym |
|
16 | Update | 2016/07/05 11:32:08 | Email Last name of contact person Last name of contact person Address Address TEL Address Address TEL Name of primary person or sponsor Organization Post marketing survey by drug manufacture etc., specified by Japanese law. Address1 Tel1 |
|
17 | Update | 2018/08/23 17:28:28 | Acronym |
|
18 | Update | 2018/08/24 10:01:18 | UMIN ID1 UMIN ID2 |
|
19 | Update | 2019/11/21 15:58:03 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Zip code Address Last name of contact person Last name of contact person Zip code Address Homepage URL Organization1 Organization Organization Address Address Tel |